Connect with us

Media & Technology

Leader in Proactive Digital Display; the Rise of VSBLTY Groupe Technologies Corp (OTCMKTS: VSBGF) (CNSX: VSBY)

Published

on

VSBLTY Groupe Technologies Corp (OTCMKTS: VSBGF) (CNSX: VSBY) is making a powerful move up the charts in recent days transforming into a volume leader in small caps. VSBLTY is the world leader in Proactive Digital Display™, which transforms retail and public spaces as well as place-based media networks with SaaS-based audience measurement and security software that uses artificial intelligence (AI) and machine learning.

The Company just reported along with Mexico’s Grupo Modelo (part of the AB InBev family of companies and owner of Budweiser, Corona, and Stella Artois) and Retailigent Media have signed a Letter of Intent to create an international in-store media network of up to 50,000 Modelorama stores and independent neighborhood bodegas in Mexico, with a potential to expand to other Central and South American countries by the end of 2027. The deployment will start in more than 5,000 Modelorama stores and 15,000 neighborhood bodegas throughout Mexico. Modelorama is Mexico’s second largest convenience store chain and is owned by Grupo Modelo.

VSBLTY Groupe Technologies Corp (OTCMKTS: VSBGF) (CNSX: VSBY) (Frankfurt: 5VS) operating out of Philadelphia, Pennsylvania is the world leader in Proactive Digital Display™, which transforms retail and public spaces as well as place-based media networks with SaaS-based audience measurement and security software that uses artificial intelligence and machine learning. This technology represents a transformative combination of rich interactive content and real-time data collection not available anywhere in a single turnkey solution. Beyond simply signage, VSBLTY allows consumers to interact with the display, manipulate content, and engage in a rich, immersive shopper experience through intuitive touch. By teaching computers how to skillfully interpret their surroundings, VSBLTY software can in turn contextualize all the information about those surroundings and deliver it to the end-user vetted and streamlined for the particular security application. One or hundreds of Persons of Interest can be identified in a large crowd in milliseconds, as well as objects including everything from backpacks to assault weapons.

VSBLTY software can be integrated with virtually any type of digital screen. Strategic partnerships have been developed with leading edge hardware manufacturers to deploy a variety of form factors to fit any solution application in retail and other public spaces. VSBLTY works hand in hand with these partners to ensure seamless integration for venues and retailers with media partners, custom display partners, field services partners, and even leasing partners when applicable to deploying a fully integrated program.

VSBLTY is co-partnering with major kiosk manufacturers to provide contactless, self-service technology to accurately and efficiently measure people for “at-risk” temperatures at the point of admittance, thereby reducing virus transmission potential between the operator and the person being scanned. VSBLTY technology adds facial recognition to thermal imaging, and the firm is working with KIOSK Information Systems, a world leader in the design and manufacture of self-service automation, and Synect, a content creation agency that enables video displays of unlimited size and scale in retail stores, airports and other complex facilities throughout the country.

VSBLTY computer vision is benchmark testing people and traffic counting in New York’s Times Square. The company is testing algorithms to determine the best utility in “Smart Cities” applications in concert with its Fortune 50 global technology partner. VSBLTY, in partnership with RadarApp, a Smart Cities Solutions provider, is beginning a production deployment in late October that leverages WIFI6 wireless infrastructure to provide high performance and low-cost surveillance connectivity. The firms are installing thousands of security kits, powered by VSBLTY software, in the multi-million dollar investment Mexico City communities are making in its safety lighting and integrated security program. VSBLTY has been selected to lead a thematic area for a global innovation, science and technology hub. More than 100 companies will be joining with several other firms selected to run industry-specific thematic areas. VSBLTY was selected to lead the Smart Retail area.

To Find out the inside Scoop on VSBLTY Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

VSBGF

Sponsored by a global brand, VSBLTY is in a Phase 1 deployment in a national drug retailer with an innovative display program to promote seasonal drug products through an internet-connected, interactive end cap solution. This sophisticated integration incorporates third party information with detailed customer and store analytics while tracking weekly sales data. Learnings from this test will help drive improved performance and increase ROI. VSBLTY Helps Create New Media Networks for Retailers

VSBLTY’s advanced technologies are not only providing retailers with immediate and comprehensive customer information but are producing a new revenue stream by selling the stores to brands as a more engaging advertising medium. There is no better place to enable brands to sell their products than where those products are on display and customers are ready to buy,” Hutton said. “Unlike any other media, retail digital signage can interact with and engage customers, even answering questions right at point of sale. A network of signage in chain stores is a very attractive advertising medium for product manufacturers.

To advance “The Stores as Media,” VSBLTY has an innovative pilot program with a U.S. East Coast grocery chain, a large deployment in a national fuel and convenience retailer in South Africa and the launch of a digital network in a convenience store chain with more than 9000 stores in Mexico. The first phase deployment began in September. In addition, the company has signed a marketing service agreement with Octagon Media Corp.

Recently VSBLTY inked an OEM agreement with Peerless-AV®, an award-winning designer and manufacturer of the highest quality audio and video solutions and accessories. The two technology companies are teaming to assimilate their solutions and services for the world’s fast-changing communications needs. Peerless-AV will be utilizing VSBLTY technology to provide enhanced customer engagement and audience measurement using machine learning and computer vision.

On December 1 VSBLTY along with Mexico’s Grupo Modelo (part of the AB InBev family of companies and owner of Budweiser, Corona, and Stella Artois) and Retailigent Media have signed a Letter of Intent to create an international in-store media network of up to 50,000 Modelorama stores and independent neighborhood bodegas in Mexico, with a potential to expand to other Central and South American countries by the end of 2027. The deployment will start in more than 5,000 Modelorama stores and 15,000 neighborhood bodegas throughout Mexico. Modelorama is Mexico’s second largest convenience store chain and is owned by Grupo Modelo.

VSBLTY Co-founder & CEO Jay Hutton said, “The three firms are partners in this long-term plan. We will be supplying all our proprietary software licensing for analytics, security and visual display. What is especially exciting is that the network will be offering major consumer product brands the opportunity to advertise to shoppers right at point-of-sale when buying decisions are made.” Hutton also said that test deployments are already underway in Mexico.

For More on VSBLTY  Subscribe Right Now!

Currently running northbound VSBLTY is an exciting story developing in small caps; VSBLTY  is making a powerful move up the charts in recent days transforming into a volume leader in small caps. VSBLTY is the world leader in Proactive Digital Display™, which transforms retail and public spaces as well as place-based media networks with SaaS-based audience measurement and security software that uses artificial intelligence (AI) and machine learning. The Company just reported along with Mexico’s Grupo Modelo (part of the AB InBev family of companies and owner of Budweiser, Corona, and Stella Artois) and Retailigent Media have signed a Letter of Intent to create an international in-store media network of up to 50,000 Modelorama stores and independent neighborhood bodegas in Mexico, with a potential to expand to other Central and South American countries by the end of 2027. The deployment will start in more than 5,000 Modelorama stores and 15,000 neighborhood bodegas throughout Mexico. Modelorama is Mexico’s second largest convenience store chain and is owned by Grupo Modelo. We will be updating VSBLTY as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with VSBLTY.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in VSBLTY either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.